PCRX - Pacira BioSciences GAAP EPS of -$0.02 misses by $0.39 revenue of $167.5M in-line
- Pacira BioSciences press release ( NASDAQ: PCRX ): Q3 GAAP EPS of -$0.02 misses by $0.39 .
- Revenue of $167.5M (+31.1% Y/Y) in-line.
- Adjusted EBITDA of $55.2M in the third quarter of 2022, compared to $48.1M in the third quarter of 2021.
- Pacira ended the third quarter of 2022 with cash, cash equivalents and available-for-sale investments of $346.1M. Cash provided by operations was $42.7M in the third quarter of 2022, compared to $60.3M in the third quarter of 2021.
For further details see:
Pacira BioSciences GAAP EPS of -$0.02 misses by $0.39, revenue of $167.5M in-line